Vygon Group, a group specialising in single-use medical devices, and Medovate, a medical device company dedicated to the development and commercialisation of innovative medical technologies, recently announced that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries. Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.
Developed in collaboration with UK National Health Service (NHS) clinicians, SAFIRA transforms the technique of Peripheral Nerve Blockade into a one-person procedure, giving the anaesthetist full control of the injection at all times. This technology also improves patient safety by helping reduce the risk of nerve damage, as it prevents anaesthetic from being injected at high pressures. Furthermore, economic modelling has shown SAFIRA has the potential to help generate significant time and cost savings in a medical setting.
Amid the current COVID-19 pandemic, the European Society for Regional Anaesthesia (ESRA) has recommended that regional anaesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. Regional anaesthesia preserves respiratory function and avoids aerosolisation and the potential for transmission of COVID-19, compared to general anaesthesia. By making regional anaesthesia a one-person procedure SAFIRA helps hospitals meet these recent recommendations.
It is estimated that ten million regional anaesthesia procedures are performed across Europe every year. As the use of regional anaesthesia continues to grow steadily across Europe, SAFIRA has the potential to make a significant impact.
For more information, please visit: https://www.vygon.com/